Welcome to our dedicated page for Alumis SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alumis Inc. (Nasdaq: ALMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Alumis is a Delaware corporation with common stock listed on The Nasdaq Global Select Market under the symbol ALMS, as noted in its Form 8‑K reports. Through this page, readers can review current and historical filings alongside AI-generated summaries designed to clarify key points in each document.
For Alumis, core filings of interest include annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which present audited or interim financial statements, details on research and development spending, collaboration revenue, and discussion of its pipeline of targeted therapies for immune-mediated diseases. Current reports on Form 8‑K, such as those describing quarterly financial results, completion of the merger with ACELYRIN, Inc., and updates to corporate presentations, provide timely information on material events and corporate actions.
Investors and analysts can also use this page to track registration statements and prospectus supplements related to Alumis’ public offerings of common stock conducted under its shelf registration statement on Form S‑3, as referenced in company press releases. Where applicable, insider transaction reports on Form 4 and proxy statements can offer additional perspective on governance and equity ownership.
Stock Titan’s AI tools help interpret lengthy filings by highlighting sections relevant to Alumis’ clinical programs, such as envudeucitinib in plaque psoriasis and systemic lupus erythematosus, A‑005 in neuroinflammatory and neurodegenerative diseases, and lonigutamab in thyroid eye disease, as described in the company’s public disclosures. Real-time updates from EDGAR ensure new ALMS filings appear promptly, while AI-powered summaries and key-point extractions can make it easier to understand financial results, merger-related disclosures, and other regulatory information without reading every page in full.
ALUMIS INC. insider filing shows internal share transfers among Foresite-affiliated entities, not market trades. Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC reported Form 4 transactions coded "J" in Common Stock on April 1, 2026, described as other acquisitions or dispositions.
Footnotes explain these were pro rata, in-kind distributions without additional consideration under Exchange Act Rules 16a-13 and 16a-9, rather than purchases or sales. Shares were distributed between entities such as Foresite Labs Affiliates 2021, LLC, Foresite Labs, LLC, and TFL Investment Holdings, LLC, with various Foresite funds and co-invest vehicles holding record ownership.
The reporting persons and related entities note that voting and dispositive power over the shares may be attributed to managing LLCs and to James B. Tananbaum in his roles, while explicitly disclaiming group status and beneficial ownership beyond any pecuniary interest.
ALUMIS INC. reported a Form 4 showing internal equity restructurings by entities associated with Foresite Capital and Foresite Labs, rather than open-market trading. On April 1, 2026, several J-code transactions moved blocks of common stock through pro rata, in-kind distributions for no cash consideration.
Labs Affiliates made in-kind distributions of shares to its members, including Foresite Labs, LLC, which then distributed shares on a pro rata basis to its own members, such as TFL Investment Holdings, LLC. Additional indirect holdings are reported for Foresite Capital Fund V, Opportunity Fund V, Fund VI, Labs Co-Invest V and Foresite Labs Fund I, all with voting and dispositive power described in the footnotes and subject to customary beneficial ownership disclaimers.
ALUMIS INC. director and 10% owner James B. Tananbaum reported a series of internal restructurings of 4,103,630 shares of common stock, coded as "J" transactions. The shares moved through pro rata, in-kind distributions among affiliated entities for no consideration and not as open-market purchases or sales.
The filing shows indirect holdings across several Foresite and Labs-related funds and LLCs, with post-transaction positions such as 5,702,536, 2,908,332, 4,247,670, 194,459 and 1,960,337 shares held of record by these entities. Tananbaum may share voting and dispositive power but consistently disclaims group status and beneficial ownership beyond his pecuniary interest.
Alumis Inc. shareholder Foresite-affiliated funds and James B. Tananbaum filed Amendment No. 4 to update their Schedule 13D. The filing reflects pro rata distributions by Foresite Labs Affiliates 2021, LLC and Foresite Labs, LLC, which reduced their Alumis common stock holdings to zero.
After these changes, James B. Tananbaum is reported to beneficially own 15,693,820 shares of Alumis common stock, representing 12.7% of the outstanding shares as of March 12, 2026. Individual Foresite funds continue to hold significant stakes, with sole voting and dispositive power attributed through their respective general partners and management entities.
The reporting group, active in venture capital investing in life sciences and healthcare, states it holds Alumis shares for investment purposes and may buy, sell, or distribute shares over time based on market conditions and its ongoing assessment of the company.
Alumis Inc. reported strong Phase 3 results for envudeucitinib, its oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. In the ONWARD1 and ONWARD2 trials, high levels of skin clearance were achieved and deepened through 24 weeks, with meaningful quality-of-life and itch improvements emerging early.
By Week 24, PASI 90 skin clearance rates reached 68.0% and 62.1%, and PASI 100 complete clearance reached 41.0% and 39.5% in envudeucitinib-treated patients. Safety and tolerability were favorable and consistent with Phase 2 data, with mostly mild, manageable side effects and no new safety signals reported.
More than 1,700 adults were enrolled across the parallel Phase 3 trials, which also showed rapid improvement in difficult-to-treat scalp psoriasis. Alumis plans to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in the second half of 2026 and is running an ONWARD3 long-term extension and the LUMUS Phase 2b trial in systemic lupus erythematosus, with topline LUMUS data expected in the third quarter of 2026.
Alumis Inc. files a shelf registration statement to permit future offerings of multiple security types. The filing registers an indeterminate number of common stock, preferred stock, debt securities and warrants under a base prospectus and a $300.0 million sales agreement with Cantor Fitzgerald & Co. dated March 18, 2026, permitting sales of voting common stock from time to time after effectiveness.
The base prospectus covers various mechanisms and convertible issuance paths; specific terms, amounts, offering prices and proceeds treatment will be disclosed in future prospectus supplements.
Alumis Inc. files its annual report describing a fast-advancing immunology pipeline and a transformative acquisition. The company focuses on targeted therapies that modulate TYK2 and other immune pathways to treat psoriasis, lupus and neuroinflammatory diseases.
Lead candidate envudeucitinib (envu) delivered positive Phase 3 psoriasis results, with about 74% of patients achieving PASI 75 and 65% achieving PASI 90 at Week 24, and was generally well tolerated. Alumis plans to submit an NDA for envu in psoriasis in the second half of 2026 and is running a global Phase 2b trial in systemic lupus erythematosus. A CNS-penetrant TYK2 inhibitor, A-005, showed favorable Phase 1 safety, and the ACELYRIN merger added lonigutamab for thyroid eye disease and net assets valued at $426.0 million in a stock transaction valued at approximately $238.1 million.
Alumis Inc. reported full-year 2025 results and major pipeline progress. Total revenue reached $24,050 thousand, driven by license and collaboration revenue, compared with no revenue in 2024. Operating expenses rose to $477,854 thousand, mainly from higher research and development and general and administrative costs.
Net loss narrowed to $243,325 thousand from $294,233 thousand, helped by a $187,907 thousand gain on bargain purchase and higher interest income. At December 31, 2025, Alumis held $89,670 thousand in cash and cash equivalents and $218,831 thousand in marketable securities.
The company highlighted positive Phase 3 topline results for envudeucitinib in moderate-to-severe plaque psoriasis and plans to submit an NDA in 2H 2026. Potentially pivotal Phase 2b topline data in systemic lupus erythematosus are anticipated in 3Q 2026. Alumis also completed an upsized public offering in January 2026, raising $345,1 million in gross proceeds.
Alumis Inc. reported that Chief Legal Officer Sanam Pangali received a stock option grant for 186,200 shares of common stock at an exercise price of $26.31 per share on January 26, 2026. These options give the right to buy Alumis shares at that price in the future.
According to the vesting terms, 25% of the shares underlying the option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, as long as the executive maintains Continuous Service under the company’s 2024 Equity Incentive Plan, with potential acceleration as provided in the plan.
Alumis Inc. reported that President, CEO and Chairman Martin Babler received a new stock option grant. On January 26, 2026, he was awarded an option to buy 745,875 shares of Alumis common stock at an exercise price of $26.31 per share, expiring January 25, 2036.
According to the vesting terms, 25% of the shares underlying this option vest on January 26, 2027. The remaining shares then vest in equal monthly installments over the following 36 months, contingent on his continuous service to Alumis and subject to possible acceleration under the company’s 2024 Equity Incentive Plan.